위궤양에 대한 레바프라잔 정제의 제3상 임상시험 = Phase III Clinical Trial of Revaprazan (Revanex？) for Gastric Ulcer

다국어 초록 (Multilingual Abstract)

Background/Aims: This randomized, double-blind, phase III, multicenter trial was carried out to compare the efficacy and safety of revaprazan, a novel acid pump antagonist, with that of omeprazole in patients with more than one of gastric ulcers. Methods: Two hundred and ninety two subjects were randomized to 4∼8 weeks of treatment with either revaprazan 200 mg or omeprazole 20 mg. The primary efficacy parameter was the cumulative healing rate determined by endoscopy after 4 and 8 weeks of treatment, and the secondary efficacy parameter was an improvement rate of pain. Results: The intention-to-treat analysis revealed revaprazan and omeprazole to have similar cumulative healing rates (93.0% and 89.6%, respectively; p=0.3038). The per-protocol analysis revealed revaprazan and omeprazole to also have similar cumulative healing rates (99.1% and 100%, respectively; p= 0.3229). In both analyses, there were no significant differences in an improvement rate of pain between the two groups. Both drugs were well tolerated. Conclusions: Revaprazan has similar efficacy to omeprazole in the treatment of patients with gastric ulcer with a once a day application of revaprazan 200 mg or omeprazole 20 mg over a 4 to 8-week period. In terms of safety, revaprazan was well tolerated. (Korean J Gastrointest Endosc 2007;34:312-319)

참고문헌 (Reference)

1 "YH1885 as a novel acid pump antagonist (APA)-toxicity studies" 52 : 62S-, 2003

2 "Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of a novel acid pump antagonist, YH1885, in Helicobacter pylori positive male subjects" 52 : 61S-, 2003

3 "The pharmacological properties of a novel acid pump antagonist, YH1885" 52 : 62S-, 2003

4 "The novel acid pump antagonists for anti-secretory actions with their peculiar applications beyond acid suppression" 38 : 1-8, 2006

5 "The effect of 7 days of dosing with YH1885 on 24-hour intragastric acidity and plasma gastrin concentration in healthy male subjects" 51 : 167S-, 2002

6 "Rules and laws of drug hepatotoxicity" 15 : 231-233, 2006

7 "Revaprazan (Revanex ), novel acid pump antagonist, for duodenal ulcer, results of a double-blind, randomized, parallel, multi-center phase III clinical trial" 31 : 17-24, 2005

8 "Phase III clinical trial of revaprazan (Revanex ) for gastritis" 33 : 212-219, 2006

9 "Pharmacologic actions of proton pump inhibitors and acid pump antagonists; implication in the treatment of Helicobacter pylori-associated gastric diseases" 5 : 113-123, 2005

10 "Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers" 44 : 73-82, 2004

11 "Pantoprazole is superior to ranitidine in the treatment of acute gastric ulcer" 30 : 111-115, 1995

12 "Lansoprazole. An update of its pharmacological properties and clinical efficacy in the ma-nagement of acid-related disorders" 54 : 473-500, 1997

13 "Lansoprazole compared with histamine2-receptor antagonists in healing gastric ulcers: a meta-analysis" 19 : 743-757, 1997

14 "Kerr GD. The correlation between acid suppression and peptic ulcer healing. Scand J Gastroenterol 1986" 125 22-29,

15 "Katon R. Treatment of benign chronic gastric ulcer with ranitidine. J Clin Gastroenterol 1986" 371-376,

16 "Hunt RH. The treatment of gastric ulcer with antisecretory drugs. Relationship of pharmacological effect to healing rates. Dig Dis Sci 1988" 619-624,

17 "Heel RC. Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders. Drugs 1991" 138-170,

18 "Discovery of a novel acid pump antagonist, YH1885" 52 : 62S-, 2003

19 "Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer-a European multicentre study" 12 : 789-795, 1998